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Anaemia and renal dysfunction are common comorbidities that 
are associated with morbidity and mortality in heart failure (HF) 
patients.[1,2] Depending on the definition used and population studied, 
the prevalence of anaemia in patients with HF ranges from 4% to 
70%.[3-5] The presence of anaemia has been associated with increased 
length of hospital stay and in-hospital mortality in HF patients.[3] 
Some studies have reported that the impact of anaemia on mortality 
tends to occur a few months after discharge.[6] Causes of anaemia in 
HF include iron deficiency, renal insufficiency, haemodilution due to 
activation of renin-angiotensin-aldosterone and vasopressin systems, 
infections such as HIV, and drugs that interfere with the synthesis 
of endogenous erythropoietin, e.g. angiotensin-converting enzyme 
inhibitors.[7,8] Both renal dysfunction and HF-associated inflamma-
tory activation are known to inhibit renal erythropoietin production, 
resulting in anaemia.[9]
Renal dysfunction, therefore, is associated with an increase in 
the prevalence of anaemia, and the two conditions are independent 
predictors of all-cause mortality in patients with HF.[2,4] Mortality 
risk is increased when both renal dysfunction and anaemia are 
present.[3] Both these conditions often coexist in HF patients.[4] 
Most of the studies on HF, however, have been from high-income 
countries (HICs), where older patients with multiple comorbid 
conditions are involved.[1,5] There is a paucity of information 
regarding the frequency of anaemia and renal dysfunction and their 
impact on in-hospital morbidity and mortality among patients with 
HF in sub-Saharan Africa (SSA). HF patients in SSA are usually 
younger (4th - 5th decade of life) than those in HICs (7th - 8th decade 
of life).[7,10] Our study aimed to estimate the frequency and impact of 
anaemia and renal dysfunction on in-hospital outcomes among HF 
patients admitted to Princess Marina Hospital (PMH), Gaborone, 
Botswana.
Methods
The study formed part of a larger observational study that 
characterised the HF population at PMH, the largest referral hospital 
in Botswana.[7] Included in the study were adult patients (≥18 years) 
admitted between February 2014 and February 2015, whose serum 
creatinine and haemoglobin results were available. No formal sample 
size calculations were done. HF was defined according to the criteria 
of the European Society of Cardiology, and decompensated HF in 
patients with a previous HF diagnosis and in those with new-onset 
HF was included. [11]
Demographic and clinical characteristics documented at admission 
include gender, age, hypertension, HIV serostatus, diabetes mellitus, 
and functional class according to the New York Heart Association 
(NYHA) criteria. Complete blood count, serum electrolyte, urea, 
creatinine and uric acid tests were performed on all enrolled patients. 
Left ventricular ejection fraction (LVEF) was calculated from the left 
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ventricular volumes obtained at end-diastole and end-systole using 
the modified biplane Simpson’s rule in the apical four-chamber and 
two- chamber views.[12] LVEF <45% was used to define significant left 
ventricular (LV) systolic dysfunction, whereas patients with LVEF >45% 
were classified as having HF with preserved ejection fraction. 
Renal dysfunction was diagnosed using an estimated glomerular 
filtration rate (eGFR) <60 mL/min/1.73 m2 body surface area on 
admission, calculated by the simplified Modification of Diet in 
Renal Disease formula.[13] Anaemia was defined as a haemoglobin 
level <13 g/dL for men and <12 g/dL for women.[14] Hospital length 
of stay (LOS) and in-hospital mortality were assessed for each 
participant. LOS was defined as the number of days from hospital 
admission to discharge.
Statistical analysis
Data were analysed using SPSS version 23.0 (IBM Corp., USA). 
Continuous variables were presented as means (standard deviations 
(SDs)) or medians and interquartile ranges (IQRs). For non-conti-
nu ous variables, absolute and relative frequencies (%) were used. 
Comparisons between continuous variables were performed using 
Student’s t-test or the Kruskal-Wallis test. Associations between 
catego rical variables were tested with the use of contingency tables 
and calculations of Pearson’s χ2, and p<0.05 was considered statisti-
cally significant. Multivariate analysis was performed using binary 
logistic regression. Covariate selection was based on plausibility and 
p<0.05 on univariate analyses.
Ethical considerations
The study was granted ethical clearance by the University of Botswana, 
the Ministry of Health and PMH Institutional Review Boards (ref. no. 
PPME 13/18/1 VIII (264)). All patients provided informed consent 
before participation. 
Results
The study included 193 patients, mostly (98.4%) black Africans 
(Table 1). The patients’ ages ranged between 20 and 89 years, with a 
mean (SD) of 54.2 (17.1) years. All patients were symptomatic and 
the majority (77.5%) presented in NYHA III or IV functional classes. 
Overall, the median (IQR) systolic and diastolic blood pressures 
were 120 (104 - 133) mmHg and 74 (67 - 82) mmHg, respectively. 
More than half (54.9%) of patients were hypertensive. A prior 
diagnosis of diabetes mellitus was present in 30 (15.5%) and often 
coexisted with hypertension. The mean LVEF was 41.7%, and about 
two-thirds (64.8%) of patients had HF with systolic dysfunction 
(LVEF <45%). 
Renal dysfunction
The median serum creatinine was 98.0 µmol/L – significantly higher 
in males than in females (105.0 µmol/L v. 87.7 µmol/L; p=0.031). 
The overall median (quartile) eGFR was 75.9 (Q1 52.5, Q3 112.4) 
mL/min/1.73 m2, with no significant gender differences. Renal 
dysfunction was detected in 60 (31.1%) patients (Table 2). In 
bivariate analysis, patients with renal dysfunction were more likely 
to be diabetic, hypertensive, and older, and had significantly greater 
serum creatinine, potassium, urea and uric acid concentrations 
than those with an eGFR ≥60 mL/min/1.73 m2. In multiple logistic 
regression analysis, patients with renal dysfunction were likely to 
have hypertension (odds ratio (OR) 2.80; 95% confidence interval 
(CI) 1.28 - 6.12; p=0.01), diabetes (OR 3.09; 95% CI 1.23 - 7.76; 
p=0.01), and lower haemoglobin levels (OR 0.85 g/dL; 95% CI 0.76 - 
0.96; p=0.008). Renal dysfunction was not associated with length of 
hospital stay (p=0.292) or in-hospital all-cause mortality (p=0.217).
Anaemia
Overall, the mean (SD) haemoglobin was 12.0 (3.0) g/dL and about 
half (54.9%) of the patients were anaemic (Table 3). Microcytic, 
normocytic and macrocytic anaemia were found in 32.1%, 57.5% and 
10.4% of patients, respectively. Of the 11 patients with macrocytic 
anaemia, 10 (90.1%) were HIV-positive and receiving antiretroviral 
medications. The mean haemoglobin level for males was significantly 
higher than for females (12.4 (3.3) g/dL v. 11.5 (2.5) g/dL; p=0.038). 
Nonetheless, the proportion of anaemic patients did not differ by 
gender (p=0.53). 
Bivariate analysis showed that patients with anaemia were more 
likely to have a higher LVEF or type 2 diabetes mellitus. Moderate to 
severe anaemia (haemoglobin <10 g/dL) was more common among 
those with renal dysfunction than in those without the condition 
(57.8% v. 23.0%; p<0.001).
The multiple logistic regression analysis indicated that patients 
with anaemia were likely to have diabetes (OR 2.68; 95% CI 1.12 
- 6.45; p=0.028) and a higher LVEF (OR 1.02; 95% CI 1.01 - 1.04; 
p=0.005). Anaemia was not associated with LOS (p=0.101) or in- 
hospital all-cause mortality (p=0.496).
Anaemia and an eGFR <60 mL/min/1.73 m2 coexisted in 
38 (19.6%) patients and was not associated with an increased 
in-hospital all-cause mortality (p=0.61) or duration of hospital 
stay (p=0.153).
Discussion
To the best of our knowledge, this is the first observational study 
of anaemia and renal failure among patients with HF admit-
ted to a hospital in Botswana. We found a high proportion of 
anaemia and renal dysfunction among patients with HF in this 
setting (54.9% and 31.1%, respectively). Neither anaemia nor 
Table 1. Clinical and demographic characteristics of patients 
with heart failure admitted to Princess Marina Hospital, 
Gaborone, Botswana
Characteristics Patients (N=193)
Male, n (%) 104 (53.9)
Age (years), mean (SD) 54.2 (17.1)
LVEF (%), mean (SD) 41.8 (20.0)
Hypertension, n (%) 106 (54.9)
Known type 2 diabetes, n (%) 30 (15.5)
Ischaemic heart disease, n (%) 11 (5.7)
Stroke, n (%) 19 (9.8)
Atrial fibrillation, n (%) 19 (9.8)
HIV-positive, n (%) 61 (33.9)
SBP (mmHg), median (Q1, Q3) 120.0 (103.8, 133.5)
DBP (mmHg), median (Q1, Q3) 74.0 (67.0, 81.5)
Haemoglobin (g/dL), mean (SD) 12.0 (3.0)
Creatinine (µmol/L), median (Q1, Q3) 98.0 (70.0, 137.5)
Urea (mmol/L), median (Q1, Q3) 8.3 (4.9, 13.7)
Uric acid (mmol/L), median (Q1, Q3) 491.5 (388.0, 623.3)
Sodium (mmol/L), mean (SD) 134.1 (6.8)
Potassium (mmol/L), mean (SD) 4.4 (0.9)
eGFR (mL/min/1.73 m2), median (Q1, Q3) 75.9 (52.5, 112.4)
LVEF = left ventricular ejection fraction; SBP = systolic blood pressure; 
DBP = diastolic blood pressure; SD = standard deviation; Q = quartile; 
eGFR = estimated glomerular filtration rate.
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renal dysfunction was significantly associated with hospital LOS 
(p=0.101) or in-hospital all-cause mortality (p=0.496). There was 
no effect on either LOS or in-hospital mortality. Remarkably, our 
cohort comprised younger patients (mean 54 years) compared 
with patients presenting in their 7th and 8th decades of life in 
the developed world.[10] This finding may in part explain why 
anaemia and renal dysfunction had a neutral effect on hospital 
outcomes, unlike in HICs. As our patients were young, they were 
likely to have fewer comorbidities and could possibly compen-
sate better for anaemia and renal dysfunction than the older HF 
cohorts in HICs.
The prevalence of anaemia among patients with HF varies between 
studies. Using the World Health Organization definition of anaemia 
in patients with HF, prevalence rates of 50 - 70% have been 
reported.[4-6,15] Most of these studies were performed in HICs 
and involved patients who are not only older than those in our 
setting, but also predominantly white.[15] We observed a prevalence 
rate >13.5% previously reported among patients with idiopathic 
cardiomyopathy in South Africa.[16] It was also higher than the 
42% reported in a study in Brazzaville, Congo, even though the 
difference may be attributed to the use of a lower cut-off value for 
anaemia (haemoglobin level <12 g/dL for men and <11 g/dL for 
Table 2. Characteristics of patients with and without reduced renal function at Princess Marina Hospital, Gaborone, Botswana
Characteristics No renal dysfunction (n=133) Renal dysfunction (n=60) p-value
Male, n (%) 74 (55.6) 30 (50.0) 0.467
Age (years), mean (SD) 52.1 (17.1) 59.0 (16.2) 0.009
LVEF (%), mean (SD) 42.1 (20.3) 41.0 (19.3) 0.735
Hypertension, n (%) 59 (44.4) 47 (78.3) <0.001
Known type 2 diabetes, n (%) 10 (7.5) 20 (33.3) <0.001
HIV-positive, n (%) 46 (34.6) 15 (25) 0.389
Ischaemic heart disease, n (%) 8 (6) 3 (5) 0.778
Stroke, n (%) 13 (9.8) 6 (10) 0.961
Atrial fibrillation, n (%) 10 (7.5) 9 (15) 0.106
Haemoglobin (g/dL), mean (SD) 12.5 (2.7) 10.9 (3.3) 0.001
SBP (mmHg), mean (SD) 119.0 (25.0) 134.0 (32.0) 0.002
DBP (mmHg), mean (SD) 74.2 (13.1) 81.1 (18.8) 0.012
eGFR (mL/min/1.73 m2), median (Q1, Q3) 98.5 (73.9, 132.1) 38.4 (14.0, 51.9) <0.001
Creatinine (µmol/L), median (Q1, Q3) 81.9 (63.0, 99.0) 179.0 (138.3, 443.5) <0.001
Urea (mmol/L), median (Q1, Q3) 6.3 (4.4, 9.4) 17.5 (11.8, 29.5) <0.001
Sodium (mmol/L), mean (SD) 134.8 (5.7) 132.4 (8.4) 0.052
Potassium (mmol/L), mean (SD) 4.3 (0.7) 4.8 (1.1) 0.004
Hospital mortality, n (%) 12 (9.0) 9 (15.0) 0.217
Length of hospital stay (days), median (Q1, Q3) 8.0 (5.0, 13.5) 9.5 (6.0, 17.0) 0.292
LVEF = left ventricular ejection fraction; SBP = systolic blood pressure; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; Q = quartile; SD = standard deviation.
Table 3. Characteristics of patients with and without anaemia at Princess Marina Hospital, Gaborone, Botswana
Characteristics Anaemia (n=107) No anaemia (n=86) p-value
Haemoglobin (g/dL), mean (SD) 9.99 (2.2) 14.4 (1.6) <0.001
Male, n (%) 55 (51.9) 49 (56.3) 0.539
Age (years), mean (SD) 53.9 (17.6) 54.7 (16.6) 0.744
LVEF (%), mean (SD) 45.5 (19.9) 37.2 (19.2) 0.004
Hypertension, n (%) 63 (59.4) 43 (49.4) 0.164
Known type 2 diabetes, n (%) 22 (20.8) 8 (9.2) 0.027
HIV-positive, n (%) 38 (35.8) 23 (26.4) 0.107
HfpEF, n (%) 52 (49.1) 29 (33.3) 0.028
MCV (fL), mean (SD) 87.7 (10.7) 89.7 (10.4) 0.190
eGFR (mL/min/1.73 m2), median (Q1, Q3) 75.5 (46.6, 119.6) 76.5 (59.8, 106.5) 0.471
Creatinine (µmol/L), median (Q1, Q3) 97.5 (67.0, 152.5) 98.0 (75.0, 123.0) 0.523
Hospital mortality, n (%) 13 (12.3) 8 (9.2) 0.496
Length of hospital stay, median (Q1, Q3) 9.0 (5.8, 16.3) 7.0 (5.0, 13.0) 0.101
LVEF = left ventricular ejection fraction; SD = standard deviation; Q = quartile; eGFR = estimated glomerular filtration rate; HfpEF= heart failure with preserved ejection fraction; 
MCV= mean corpuscular volume.
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women).[17] The proportion of patients with anaemia in this study 
is lower than the 63.3% reported in Uganda.[18] Direct comparison 
of different studies is nevertheless difficult owing to the variation 
of both anaemia cut-off values and the populations studied. In HIC 
populations, anaemia is caused by age-related chronic diseases and 
renal dysfunction.[4,15,19] Our population was young and included a 
higher proportion of females of reproductive age. The prevalence 
of anaemia among non-pregnant women in Africa is about 41%, 
the highest in the world.[20] Even though the prevalence of anaemia 
was high among HF patients in our study, its significance for public 
health screening remains doubtful owing to lack of effect in hospital 
outcomes. It is therefore imperative that each HF patient with 
anaemia is recognised by healthcare workers in the hospital setting 
and managed accordingly.
Low haemoglobin levels have been reported to be an independent 
predictor of mortality.[2,21] While in-hospital mortality and LOS were 
not associated with anaemia in our study, we have previously reported 
an increase in 6-month mortality when these patients were followed 
up.[7] A similar finding, where in-hospital mortality was similar for 
anaemic and non-anaemic patients but with a higher mortality 1 year 
after discharge, has previously been reported by De Amicis et al.[6] 
The median hospital LOS in our study was not significantly longer in 
anaemic patients than in non-anaemic participants (8.0 days v. 
9.5 days; p=0.292). Our observation is in agreement with the findings 
of De Amicis et al.[6] that anaemia is not associated with an increase in 
hospital LOS. Our result, however, differs from that of Caug hey et al.,[5] 
who found an increase in hospital mortality and LOS among patients 
with acute decompensated HF. The discrepancy in these findings 
is possibly owing to differences in the characteristics of HF cohorts 
studied. The young age of our patients may partially protect them from 
increased mortality or prolonged LOS. 
Type 2 diabetes mellitus, a high LVEF or HF with preserved ejection 
fraction has been reported to be associated with anaemia in HF.[6,21] 
Our study demonstrated a significant association between anaemia 
with type 2 diabetes and LVEF after adjusting for other factors. 
Diabetes mellitus has been associated with anaemia of chronic disease, 
a common presentation among patients with HF.[22] Other known 
causes of anaemia in HF include iron deficiency, renal insufficiency, 
haemodilution due to activation of renin-angiotensin-aldosterone and 
vasopressin systems, infections such as HIV, and drugs that interfere 
with the synthesis of endogenous erythropoietin, e.g. angiotensin-
converting enzyme inhibitors.[7,8] As our study included patients with 
new-onset HF, who enrolled before the initiation of HF medications, 
haemodilution is a possible cause of anaemia in this group. Although 
about a third of the study participants were HIV-infected, the 
infection was not significantly associated with anaemia. Macrocytic 
anaemia was, however, more common among HIV-infected patients, 
most likely due to the use of azidothymidine.[23]
We found that a third of participants had renal dysfunction, 
comparable to the findings of the sub-Saharan Africa Survey of 
Heart Failure (THESUS-HF), in which 30.6% of HF patients had 
renal dysfunction when admitted to hospital.[24] Similarly, in a meta-
analysis of 65 324 HF patients, moderate to severe renal impair-
ment was found in up to 29% of all patients, the prevalence being 
lower in outpatients than hospitalised patients.[1] In addition to 
structural renal abnormalities related to hypertension, diabetes or 
atherosclerosis, renal dysfunction in HF patients may result from 
renal hypoperfusion caused by haemodynamic, neurohumoral and 
inflammatory factors.[9,25] We also found that systolic and diastolic 
blood pressures were significantly high among patients with reduced 
renal function, possibly explained by the underlying hypertension. 
Hypertension and diabetes mellitus (both risk factors for kidney 
disease) were common in patients with renal dysfunction.[26] This 
is consistent with findings in previous studies that suggested a 
progressive increase in the prevalence of hypertension and diabetes, 
with reduction in kidney function.[26] Our study also confirmed 
the findings that a decline in renal function is associated with an 
increase in the prevalence of anaemia in HF patients.[4] Both renal 
dysfunction and HF-associated inflammatory activation inhibit 
renal erythropoietin production.[9] Moderate to severe anaemia 
(haemoglobin <10 g/dL) was more commonly seen among patients 
with renal dysfunction than in those without. 
Renal dysfunction has been associated with longer hospital stay 
and increased hospital mortality in patients with HF.[1,24,27] We found 
an insignificant increase in mortality and length of hospital stay in 
patients with renal dysfunction, possibly owing to our sample size. 
Furthermore, estimation of renal function was done at enrolment, 
using a single (baseline) serum creatinine value. In the setting of 
acute or decompensated HF, it is possible to misclassify patients with 
unstable renal dysfunction who recover with improvement in HF. As 
our participants were young, they were more likely to have unstable 
renal dysfunction, and potentially recovered without any effect on 
mortality or length of hospital stay.
Conclusion
The current study has demonstrated a high frequency of anaemia and 
renal dysfunction among HF patients admitted to a tertiary hospital 
in Botswana. Both anaemia and renal dysfunction were, however, not 
predictors of LOS or in-hospital mortality. There is a need for large 
studies in SSA to confirm findings from HICs, as data from western 
cohorts may not necessarily apply to SSA because of the differences 
in HF populations. 
Study limitations
This study was undertaken in a small city (Gaborone) and therefore 
limited by the relatively small number of patients. As this was part 
of previous research, there was no sample size calculation. However, 
the study provides useful insights that open new avenues for future 
studies of HF. All deaths were assumed to be attributable to HF, 
which is likely to be an overestimation because of other significant 
medical comorbidities that were highly prevalent in our patients. 
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